IL33 and asthma: Currently, there has been an influx of biologic treatments for asthma targeting cytokines that are notable drivers for asthma exacerbation, such as tezepelumab (anti-TSLP), astegolimab (anti-ST2), itepekimab (anti-IL-33), and risankezumab (anti-IL-23) (7–10).